Objective, reproducible, and trustworthy data in clinical trials with imaging endpoints

Dr. Anthony Tolcher, medical oncologist and CEO of NEXT Oncology, spoke to us about objectivity as one of the biggest challenges in clinical trials and how a software solution for tumor assessment can improve the quality and reproducibility of data, all while saving time.

Moreover, such software solutions are a key aspect for the approval of novel drugs based on small sample size – like for example targeted or tissue agnostic medicine, as a significant advance for precision therapies. Dr. Tolcher describes how mint Lesion™ assists in generating trustworthy data, “so that [one] can ensure that the drugs that are getting approved really do work.”

Click here or on the image above to watch the full video on YouTube.

Structured Reporting Clinical Trials Standardized Reading Procedures Therapy Response Assessment Video

Related Resources

Related Resources

mint Lesion's Research Suite: advanced imaging research platform designed to support

mint Lesion Research Suite: The Flexible Imaging Research Platform Built for Scalable, Single- and Multi-Center Studies

mint Lesion's Research Suite is an advanced imaging research platform designed to support academic teams in streamlining and scaling their imaging…

Image of doctor looking at a prostate in mint Lesion.

Structured Reporting and AI in Radiology: Efficiency and Quality in Prostate Diagnostics

How are structured reporting and artificial intelligence transforming radiology practice? Prof. Dr. Thorsten Persigehl from University Hospital…

Dr. Madelaine Hettler from University Medical Center Mannheim discusses the RACOON-SAGA project and how it improves sarcoma diagnostics.

Rare Tumors, Big Goals: How RACOON-SAGA Aims to Improve Therapy Decisions

Rare tumors, major challenges: The RACOON-SAGA project explores how imaging and clinical data can improve the pre-therapeutic characterization of soft…